Loading...
•
Jun 29
Teleflex Q2 2025 Earnings Report
Teleflex reported solid second quarter 2025 financial results, with increases in constant currency revenue growth and adjusted earnings per share compared to the prior year period.
Key Takeaways
Teleflex delivered a strong second quarter in 2025, with GAAP revenue reaching $780.9 million, a 4.2% increase year-over-year. Adjusted diluted EPS from continuing operations rose to $3.73, up from $3.42 in the prior year. The company also raised its full-year 2025 guidance for both GAAP and adjusted constant currency revenue growth, as well as GAAP and adjusted diluted EPS, primarily driven by the recent acquisition of BIOTRONIK's Vascular Intervention business.
GAAP revenue for Q2 2025 was $780.9 million, marking a 4.2% increase compared to the same period last year.
Adjusted diluted EPS from continuing operations for Q2 2025 increased to $3.73, up from $3.42 in Q2 2024.
The acquisition of BIOTRONIK's Vascular Intervention business significantly contributed to the raised full-year 2025 revenue guidance.
Interventional product category showed strong growth with a 20.4% increase in revenue year-over-year.
Teleflex
Teleflex
Teleflex Revenue by Segment
Teleflex Revenue by Geographic Location
Revenue by Segment
Americas Segment Revenue
CapyFin.comEMEA Segment Revenue
CapyFin.comAsia Segment Revenue
CapyFin.comRevenue by Geographic Location
Vascular Access Revenue
CapyFin.comInterventional Revenue
CapyFin.comAnesthesia Revenue
CapyFin.comSurgical Revenue
CapyFin.comInterventional Urology Revenue
CapyFin.comOEM Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
Teleflex has increased its full-year 2025 guidance for GAAP revenue growth to 9.00% to 10.00% and adjusted constant currency revenue growth to 7.70% to 8.70%. GAAP diluted EPS from continuing operations guidance is raised to $6.73 to $7.13, and adjusted diluted EPS from continuing operations guidance is raised to $13.90 to $14.30.
Positive Outlook
- Raised GAAP revenue growth guidance range to 9.00% to 10.00% for full year 2025.
- Raised adjusted constant currency revenue growth guidance range to 7.70% to 8.70% for full year 2025.
- Raised GAAP EPS from continuing operations guidance range to $6.73 to $7.13 for full year 2025.
- Raised adjusted diluted EPS from continuing operations guidance range to $13.90 to $14.30 for full year 2025.
- Acquisition of BIOTRONIK's Vascular Intervention business is expected to generate $204 million in revenue in the second half of 2025.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the provided text, as the outlook was generally positive due to the acquisition and improved performance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income